A Multi Case Study Of Globalization Path Of Japanese Emerging Bio Medical Firms

The aging of the world makes the development of health industry. Under the background of the globalization of the market and the strong support of the Japanese government, the internationalization of the Japanese new bio pharmaceutical enterprises will become more and more active. In order to improve the core competitiveness of enterprises in the international market, enterprises need to choose their own international routes in the development of internationalization. To this end, this study focuses on three issues:(1) enterprises through what path to go out; (2) under what kind of conditions to choose the path; (3) where is the difference between the international path of the enterprise.This research combines with the existing theory, chooses in the Tokyo securities listed companies have international behavior, and more typical of the three emerging bio pharmaceutical companies, through multiple case studies to analyze the characteristics, differences and reasons behind the internationalization of enterprises. The study found that:Three companies because of their own advantages, positioning, scale, technology and research and development capabilities of different, in the process of internationalization produce different path selection. In addition, as a result of biological pharmaceutical enterprises have high technology, high investment, long product development cycle, high risk, and so on, In order to enhance the enterprise’s own ability, reduce and disperse the risk in the process of growing up, Three companies through international to obtain overseas resources, technology, participate in international research and development, to open up the global market at the same time, integration of domestic resources.